BACKGROUND: Oxidative stress may contribute to the development of heart failure (HF); however, an increased risk of HF has been observed with antioxidant therapy in secondary prevention trials. No large clinical trials have addressed the role of antioxidant therapy in the primary prevention of HF. METHODS AND RESULTS: We examined the effect of vitamin E and HF risk in 39 815 initially healthy women, aged at least 45 years at baseline, who were enrolled in the Women's Health Study, a randomized, double-blind, placebo-controlled trial of vitamin E (600 IU every other day). Over a median follow-up of 10.2 years, there were 220 incident HF events. In proportional hazards models, adjusting for age and randomized aspirin and beta carotene treatment, vitamin E assignment did not significantly affect HF risk (hazards ratio [HR], 0.93; 95% CI, 0.71-1.21; P=0.59). These results did not change with multivariate adjustment for other risk factors, including interim myocardial infarction. In a prespecified subgroup analysis, vitamin E was inversely related to developing HF with normal ejection fraction (≥50%) with HR 0.59 (95% CI, 0.38-0.92; P=0.02), but there was no statistically significant effect on the risk of developing systolic HF (HR, 1.26; 95% CI, 0.84-1.89; P=0.26). CONCLUSIONS: In this population of apparently healthy women, vitamin E did not affect the overall risk of HF. The possible benefit on diastolic HF requires confirmation in larger populations. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000479.
RCT Entities:
BACKGROUND: Oxidative stress may contribute to the development of heart failure (HF); however, an increased risk of HF has been observed with antioxidant therapy in secondary prevention trials. No large clinical trials have addressed the role of antioxidant therapy in the primary prevention of HF. METHODS AND RESULTS: We examined the effect of vitamin E and HF risk in 39 815 initially healthy women, aged at least 45 years at baseline, who were enrolled in the Women's Health Study, a randomized, double-blind, placebo-controlled trial of vitamin E (600 IU every other day). Over a median follow-up of 10.2 years, there were 220 incident HF events. In proportional hazards models, adjusting for age and randomized aspirin and beta carotene treatment, vitamin E assignment did not significantly affect HF risk (hazards ratio [HR], 0.93; 95% CI, 0.71-1.21; P=0.59). These results did not change with multivariate adjustment for other risk factors, including interim myocardial infarction. In a prespecified subgroup analysis, vitamin E was inversely related to developing HF with normal ejection fraction (≥50%) with HR 0.59 (95% CI, 0.38-0.92; P=0.02), but there was no statistically significant effect on the risk of developing systolic HF (HR, 1.26; 95% CI, 0.84-1.89; P=0.26). CONCLUSIONS: In this population of apparently healthy women, vitamin E did not affect the overall risk of HF. The possible benefit on diastolic HF requires confirmation in larger populations. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000479.
Authors: Yuji Okura; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Richard J Rodeheffer Journal: J Clin Epidemiol Date: 2004-10 Impact factor: 6.437
Authors: Theophilus E Owan; David O Hodge; Regina M Herges; Steven J Jacobsen; Veronique L Roger; Margaret M Redfield Journal: N Engl J Med Date: 2006-07-20 Impact factor: 91.245
Authors: I-Min Lee; Nancy R Cook; J Michael Gaziano; David Gordon; Paul M Ridker; Joann E Manson; Charles H Hennekens; Julie E Buring Journal: JAMA Date: 2005-07-06 Impact factor: 56.272
Authors: Nancy R Cook; I-Min Lee; J Michael Gaziano; David Gordon; Paul M Ridker; JoAnn E Manson; Charles H Hennekens; Julie E Buring Journal: JAMA Date: 2005-07-06 Impact factor: 56.272
Authors: Roberto Marchioli; Giacomo Levantesi; Alejandro Macchia; Rosa Maria Marfisi; Gian Luigi Nicolosi; Luigi Tavazzi; Gianni Tognoni; Franco Valagussa Journal: J Cardiovasc Med (Hagerstown) Date: 2006-05 Impact factor: 2.160
Authors: R Sacha Bhatia; Jack V Tu; Douglas S Lee; Peter C Austin; Jiming Fang; Annick Haouzi; Yanyan Gong; Peter P Liu Journal: N Engl J Med Date: 2006-07-20 Impact factor: 91.245
Authors: Tien Y Wong; Wayne Rosamond; Patricia P Chang; David J Couper; A Richey Sharrett; Larry D Hubbard; Aaron R Folsom; Ronald Klein Journal: JAMA Date: 2005-01-05 Impact factor: 56.272
Authors: Francesca Bursi; Susan A Weston; Margaret M Redfield; Steven J Jacobsen; Serguei Pakhomov; Vuyisile T Nkomo; Ryan A Meverden; Véronique L Roger Journal: JAMA Date: 2006-11-08 Impact factor: 56.272
Authors: Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring Journal: N Engl J Med Date: 2005-03-07 Impact factor: 91.245
Authors: Neal A Chatterjee; Claudia U Chae; Eunjung Kim; M Vinayaga Moorthy; David Conen; Roopinder K Sandhu; Nancy R Cook; I-Min Lee; Christine M Albert Journal: JACC Heart Fail Date: 2017-06-14 Impact factor: 12.035
Authors: Tracy L Kinsey; Til Stürmer; Michele Jonsson Funk; Charles Poole; Ross J Simpson; Robert J Glynn Journal: Rheumatology (Oxford) Date: 2020-09-01 Impact factor: 7.580
Authors: Njabulo Ngwenyama; Annet Kirabo; Mark Aronovitz; Francisco Velázquez; Francisco Carrillo-Salinas; Ane M Salvador; Tania Nevers; Venkataraman Amarnath; Albert Tai; Robert M Blanton; David G Harrison; Pilar Alcaide Journal: Circulation Date: 2021-01-19 Impact factor: 29.690